Levroxa Syrup contains Levetiracetam 100mg/ml, an antiepileptic agent indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in adults and pediatric patients. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby stabilizing neuronal activity and reducing seizure frequency. Levroxa Syrup offers a convenient oral liquid formulation, facilitating accurate dosing in patients who have difficulty swallowing tablets, including children and elderly individuals. The syrup is rapidly absorbed, with peak plasma concentrations achieved within one hour post-administration, and exhibits linear pharmacokinetics with minimal protein binding. It is primarily eliminated unchanged via renal excretion, necessitating dose adjustments in patients with renal impairment. Levroxa Syrup is generally well tolerated; common adverse effects include somnolence, dizziness, headache, and fatigue. Caution is advised in patients with a history of psychiatric disorders, as behavioral abnormalities have been reported. Levroxa Syrup should be used under medical supervision, with regular monitoring to optimize therapeutic outcomes and minimize adverse effects. It is essential to adhere to prescribed dosing schedules and not discontinue therapy abruptly to prevent seizure exacerbation.